Vascular Diseases  >>  Ovidrel (choriogonadotropin alfa)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ovidrel (choriogonadotropin alfa) / EMD Serono
REGENESIS, NCT00663416: (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

Terminated
2b
134
Canada, RoW
NTx™-265: rhCG, then rEPO, Ovidrel, Eprex, Saline placebo, Sodium Chloride 0.9%
Stem Cell Therapeutics Corp.
Stroke
10/08
01/09
REGENESIS-LED, NCT00938314: Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

Terminated
2b
96
US, Canada, RoW
human chorionic gonadotropin (hCG), then epoetin alfa (EPO), Ovidrel, Ovitrelle, Epogen, Eprex, Saline Placebo, Sodium Chloride 0.9%
Stem Cell Therapeutics Corp.
Stroke
04/10
04/10
REGENESIS, NCT00715364: (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

Withdrawn
2b
30
US
NTx™-265: rhCG, then rEPO, Ovidrel, Epogen, Saline Placebo, Sodium Chloride 0.9%
Stem Cell Therapeutics Corp.
Stroke
06/10
09/10

Download Options